e-learning
resources
European Respiratory Review
2020
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
Manuela Platé, Delphine Guillotin, Rachel C Chambers
Source:
Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020
Journal Issue:
September
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Manuela Platé, Delphine Guillotin, Rachel C Chambers. The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis. Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
The promise of mTOR signaling as a therapeutic target for IPF
Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference
Year: 2020
CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis
Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Year: 2018
The matrix-fibroblast interplay contributes to HIF-1 alpha pathway activation: a possible therapeutic target in idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – Elucidating the mechanisms underlying lung repair and exploring therapeutic strategies in vitro
Year: 2020
Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies
Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019
Year: 2019
The lung epithelium is a prominent source of Wnt ligands and inhibitors in idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Vascular and interstitial remodelling in chronic lung disease: therapeutic interventions on the horizon
Year: 2008
ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses
Source: Annual Congress 2010 - Lung cell biology and immunology
Year: 2010
Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension
Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019
Year: 2021
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities
Source: Eur Respir J 2014; 44: 513-522
Year: 2014
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Targeting the mTOR signaling pathway to inhibit lung cell senescence in chronic obstructive pulmonary disease (COPD)
Source: ERS Lung Science Conference 2017
Year: 2017
Calcium-sensing receptor as a therapeutic target for pulmonary fibrosis
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Potential new biomarkers for idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Fibrocytes: potential new therapeutic targets for pulmonary hypertension?
Source: Eur Respir J 2010; 36: 1232-1235
Year: 2010
PP208 – SRC family kinases modulate molecular pathways associated with mitochondrial dysfunction in idiopathic pulmonary fibrosis
Source: ERS Lung Science Conference 2021
Year: 2021
Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis
Source: Eur Respir J, 57 (4) 2000652; 10.1183/13993003.00652-2020
Year: 2021
mTOR signalling is an essential pathway for TGF-β1 induced collagen synthesis
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept